Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients

Radiotherapy and Oncology

Volumn 92, Issue 1, 2009, Pages 62-67

  Kassim, Iskandar ^a   Dirkx, Maarten L P ^a   Heijmen, Ben J M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Prostate cancer; Treatment margins; Treatment planning

Indexed keywords

ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DOSIMETRY; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION EXPOSURE; RECTUM; SEMINAL VESICLE; TREATMENT PLANNING; TREATMENT RESPONSE;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, CONFORMAL; RECTUM; THERMOLUMINESCENT DOSIMETRY;

EID: 66949158630     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.02.004     Document Type: Article

References (25)

1. Boyer A.L., Butler E.B., DiPetrillo T.A., et al. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 51 (2001) 880-914
2. Dragun A., Harmon J., and Aguero E. Defining targets and protecting normal tissues in inverse-planned IMRT for prostate, head and neck, and gynecologic cancers: a comparative review. ComOncol 2 (2005) 299-306
3. International Commission on Radiation Units and Measurements (ICRU). ICRU-62. Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50). Washington, DC: ICRU; 1999.
4. Stroom J.C., and Heijmen B.J.M. Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. Radiother Oncol 64 (2002) 75-83
5. Zelefsky M.J., Fuks Z., Happersett L., et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 55 (2000) 241-249
6. Peeters S.T.H., Heemsbergen W.D., Koper P.C.M., et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 24 (2006) 1990-1996
7. Al Mamgani A., van Putten W.L.J., Heemsbergen W.D., et al. Update of Dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 72 (2008) 980-988
8. Epstein J.I., Walsh P.C., Carmichael M., et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
9. Michael E., and Chen D. Detailed mapping of prostate carcinoma foci. Cancer 89 (2000) 1800-1809
10. Peeters S.T.H., Heemsbergen W.D., van Putten W.L.J., et al. Acute and late complications after radiotherapy for prostate cancer: results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 61 (2005) 1019-1034
11. Peeters S.T.H., Hoogeman M.S., Heemsbergen W.D., et al. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 66 (2006) 11-19
12. Mutanga T.F., de Boer H.C.J., van der Wielen G.J., et al. Stereographic targeting in prostate radiotherapy: speed and precision by daily automatic positioning corrections using kilovoltage/megavoltage image pairs. Int J Radiat Oncol Biol Phys 71 (2008) 1074-1083
13. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 62 (2005) 1297-1308
14. Huang E.H., Pollack A., Levy L., Starkschall G., Dong L., Rosen I., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54 (2002) 1314-1321
15. Niemierko A. Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24 (1997) 103-110
16. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res Suppl 8 (1985) S13-S19
17. Kutcher G.J., Burman C., Brewster L., Goitein M., and Mohan R. Histogram reduction method for calculating complication probabilities for three-dimensional treatment planning evaluations. Int J Radiat Oncol Biol Phys 21 (1991) 137-146
18. Fenoglietto P., Laliberte B., Allaw A., Ailleres N., Idri K., Hay M.H., et al. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk. Radiother Oncol 88 (2008) 77-87
19. Butler E.B., Teh B.S., Grant III W.H., et al. Smart (simultaneous modulated accelerated radiation therapy) boost: a new accelerated fractionation schedule for the treatment of head and neck cancer with intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys 45 (1999) 21-32
20. Dirkx M.L.P., de Koste J., and Senan S. A treatment planning study evaluating a simultaneous integrated boost' technique for accelerated radiotherapy of stage III non-small cell lung cancer. Lung Cancer 45 (2004) 57-65
21. Pos F.J., van Tienhoven G., Hulshof M.C.C.M., et al. Concomitant boost radiotherapy for muscle invasive bladder cancer. Radiother Oncol 68 (2003) 75-80
22. Dale R.G., and Jones B. Is the [alpha]/[beta] for prostate tumors really low? In regard to Fowler et al., IJROBP 2001;50:1021-31. Int J Radiat Oncol Biol Phys 52 (2002) 1427-1428
23. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low [alpha]/[beta] ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
24. Pos F.J., Hart G., Schneider C., et al. Radical radiotherapy for invasive bladder cancer: what dose and fractionation schedule to choose?. Int J Radiat Oncol Biol Phys 64 (2006) 1168-1173
25. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 56 (2003) 1093-1104